Antibiotic-Refractory Chronic Pouchitis After Ileal Pouch-Anal Anastomosis: Current and Emerging Therapeutic Strategies. (PubMed, Drugs) - Sep 17, 2026 - "Vedolizumab is the only advanced therapy approved in Europe for chronic pouchitis, whereas evidence for tumor necrosis factor (TNF) antagonists, ustekinumab, and newer agents, such as interleukin (IL)-23p19 antagonists and Janus kinase (JAK) inhibitors is largely based on observational data from clinical practice and real-world experience. Overall, current management strategies for chronic pouchitis are limited by incomplete understanding of disease pathogenesis, and by persistent methodological gaps, including poorly standardized treatment outcomes and the lack of validated treat-to-target strategies for this population. Well designed prospective and controlled studies are needed to define appropriate antibiotic-sparing strategies, optimal treatment positioning, and long-term durability of response."
Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Oncology • Transplantation
|
|
Christopher Ma; Connor Tuttle; Ilaria Faggiani; Iris Dotan; Laurent Peyrin-Biroulet; Remo Panaccione; Rocío Sedano; Silvio Danese; Vipul Jairath
|